A prospective, randomized, controlled trial of @entity229 for XXXX .

@entity1 @entity229 @entity384 @entity1000 @entity2719
Although @entity229 has been used to treat @entity1 with @entity1000 , its efficacy has not been rigorously studied. We therefore randomly assigned 102 @entity1 to either treatment with @entity229 (60 mg per day) or a control group. At three months, improvement, defined prospectively as an increase in the ejection fraction of greater than or equal to 5 percentage points, was observed in 53 percent of the @entity1 receiving @entity229 and 27 percent of the controls (P = 0.005). The mean (+/- SE) ejection fraction increased 4.3 +/- 1.5 percentage points (from 17.9 +/- 1.0 to 22.2 +/- 1.6 percent) in the @entity229 group, as compared with 2.1 +/- 0.8 percentage points (from 17.1 +/- 1.1 to 19.3 +/- 1.4 percent) in the control group (P = 0.054). All @entity1 were categorized prospectively in two separately randomized subgroups. "Reactive" @entity1 (n = 60) were those who had fibroblastic (n = 36) or lymphocytic (n = 2) infiltration or immunoglobulin deposition (n = 16) on endomyocardial biopsy, a positive @entity2719 scan (n = 7), or an elevated erythrocyte sedimentation rate (n = 18). "Nonreactive" @entity1 (n = 42) had none of these features. At three months, 67 percent of the reactive @entity1 who received @entity229 had improvement, as compared with 28 percent of the reactive controls (P = 0.004). Nonreactive @entity1 did not improve significantly with @entity229 (P = 0.51). After three months, reactive @entity1 who received @entity229 daily were switched to alternate-day therapy (60 mg every other day), and after six months the improvement seen earlier was no longer present. These data suggest that @entity1 with @entity1000 may have some improvement when given a high dose of @entity229 daily. However, the increases in the ejection fraction that we observed during @entity229 treatment were small, their duration was limited, and the side effects were important. Overall, @entity229 was judged to have only marginal clinical benefit, and should not be administered as standard therapy for @entity384 .
